Start-Up Quarterly Statistics, Q3 2012
This article was originally published in Start Up
In the third quarter of 2012, start-up companies raised a total of $682 million across all industries, roughly 19% more than in the previous quarter. Of that money, 65% went to biopharmas. Several large molecule-focused companies inked deals during Q3. Four start-ups were acquired – three biopharmas and one medical device company.
You may also be interested in...
Third Rock is the sole Series A investor in MyoKardia, which plans to use personalized medicine to treat hypertrophic and dilated cardiomyopathies.
Earlier than anticipated exit for Elevation means less dilution for its venture capital backers, who had provided $30 million in Series B funds this past January.
The recently spun-out company raised money to fund two Phase II trials in hopes of garnering a partner for its diabetic macular edema drug.